Pour les patients

Actualité

Dernieres Publications
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What’s new 12 months later?
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What’s new 12 months later?
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

Nos dernières publications
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What’s new 12 months later?
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

Nos derniers essais cliniques

CAPRIH : début en 2024

Cohorte institutionnelle. Cohorte multicentrique chez les patients ayant un cancer primiti hépatique rare Investigateur principal:...

IMMUNO-TH : début en 2024

Essai institutionnel Étude multicentrique ouverte de phase 2 testant l’atezolizumab bevacizumab après récidive d’un CHC...

Nos dernières rencontres

Journée du 13 juin 2024

Description
Dans le cadre des rencontres du PLCG, nous avons le plaisir d’organiser la journée le jeudi 13 juin 2024, à partir de 15h Amphithéatre Caroli de l’Hôpital Saint-Antoine à Paris.
le programme
En savoir plus ...
Date: 2024-06-13
Lieu: Hôpital Saint-Antoine

Journée soutenue par:

Journée du 7 décembre 2023

Description
Dans le cadre des rencontres du PLCG, nous avons le plaisir d’organiser la prochaine journée le jeudi 07 décembre 2023, à l’Hôpital Saint-Antoine à Paris, avec comme invité exceptionnel le Professeur Jordi Bruix, l’inventeur du BCLC !
le programme
En savoir plus ...
Date: 2023-12-07
Lieu: Hôpital Saint-Antoine

Journée soutenue par:

Gilead_Sciences-Logo.wine
astrazeneca
Logo_Bayer.svg

Pour les patients

Découvrez notre encyclopédie d’articles sur différents cas médicaux

explication pédagogique sur les maladies et les traitements

Newsletter

Restez informé des dernières nouvelles

Contactez nous

  • Paris, France
  • contact@parislivercancergroup.com
Pour les patients

Fermer